ADCs 依赖内吞作用传递有效载荷，这限制了其向靶细胞内输送细胞毒性药物的能力，而且有效载荷的固有毒性制约了最大耐受剂量；CAR - T 和 BiTE 疗法虽然在血液系统 ... 性抗体能同时靶向肿瘤相关抗原和死亡受体 5（DR5 或 TNFRSF10B，TRAILR2）。此次研究的主角是 ...

ONK’s most advanced candidate is ONKT101, which targets CD19 and features a membrane bound DR5 TRAIL variant. First-generation CAR-T cell therapies have shown the potential of targeting CD19 to ...